Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22052763 | 1.00 | TDP1 (0.36) | TDP1AKR1C3AKR1C2GFERALDH1A1 | |
| SCHEMBL24667087 | 1.00 | TDP1 (0.36) | TDP1AKR1C3AKR1C2GFERALDH1A1 | |
| SCHEMBL22052762 | 1.00 | TDP1 (0.36) | TDP1AKR1C3AKR1C2GFERALDH1A1 | |
| SCHEMBL25033728 | 0.90 | TDP1 (0.43) | TDP1GFERALDH1A1 | |
| SCHEMBL21740354 | 0.86 | CHRM2 (0.35) | TDP1AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL12283890 | 0.78 | ALDH1A1 (0.39) | TDP1AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL2319362 | 0.78 | ALDH1A1 (0.39) | TDP1AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL12283793 | 0.78 | AKR1C3 (0.43) | AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL2318844 | 0.78 | AKR1C3 (0.43) | AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL19277298 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2022261243-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2020112872-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | TDP1 1316/4885AKR1C3 3792/4885AKR1C2 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.